Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Stukalin

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancerAnnalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and EthnicityMallik Greene, Brad Stieber, A Burak Ozbay, et al.
Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Gastroenterology|December 19, 2021
Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030)Igor Stukalin, Newaz Shubidito Ahmed, Adam M Fundytus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative TherapyJenny J Ko, Brandon Bernard, Ben Tran, et al.
JAMA Network Open|December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination ImmunotherapyAlexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Current Oncology (Toronto, Ont.)|February 24, 2021
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular CancerDomen Ribnikar, Igor Stukalin, Philippe L Bedard, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancerAnnalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and EthnicityMallik Greene, Brad Stieber, A Burak Ozbay, et al.
Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Gastroenterology|December 19, 2021
Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030)Igor Stukalin, Newaz Shubidito Ahmed, Adam M Fundytus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative TherapyJenny J Ko, Brandon Bernard, Ben Tran, et al.
JAMA Network Open|December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination ImmunotherapyAlexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Current Oncology (Toronto, Ont.)|February 24, 2021
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular CancerDomen Ribnikar, Igor Stukalin, Philippe L Bedard, et al.
Pageof 4